Bristol Myers Squibb BMY and partner bluebird bio, Inc. BLUE announced that the FDA has refused to review their biologics license application (“BLA”) for CAR-T therapy candidate, idecabtagene ...
Gilead Sciences, Inc. GILD announced that the FDA accepted Kite’s Biologics License Application (BLA) and granted Priority Review designation to investigational chimeric antigen receptor (CAR) T cell ...
Like anyone with two eyes and a stomach, I've longed to visit San Sebastián, the city with the most Michelin stars per capita in Europe. But getting there? Let’s just say there’s a reason gastronomes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback